Literature DB >> 24150822

["With all suitable means". Off-label-use and public statutory employers' liability insurance].

C Skudlik1, B Lindemann, M Woltjen, S Brandenburg, S M John.   

Abstract

In Germany, responsibility for treatment of occupational diseases lies with the public statutory employers' liability insurances (SELI). According to their legal obligation SELI have to ascertain cure--wherever possible--"with all suitable means". Thus, dermatologists treating patients with occupational dermatoses are required to deliver the best possible therapy, which, according to the current scientific knowledge, may in some cases be off-label. For example, in occupational contact dermatitis a number of scientifically promising topical and systemic drugs are not yet licensed for this indication. Off-label prescribing is not prohibited and there are no laws limiting physician flexibility in such prescribing. SELI also allows the use of off-label drugs. The goals of optimal treatment or effective prevention of occupational disease determine the measures which can be employed. Off-label use is approved for occupational skin diseases when the medication is required for cure or prevention and its use meets generally accepted medical standards. In these cases, SELI will cover off-label drug prescriptions. However, detailed patient counseling and informed consent are mandatory.

Entities:  

Mesh:

Year:  2013        PMID: 24150822     DOI: 10.1007/s00105-013-2592-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  23 in total

Review 1.  Allergic contact dermatitis in children: a practical approach to management.

Authors:  A L Bruckner; W L Weston
Journal:  Skin Therapy Lett       Date:  2002-10

Review 2.  Treatment of irritant and allergic contact dermatitis.

Authors:  David E Cohen; Noushin Heidary
Journal:  Dermatol Ther       Date:  2004       Impact factor: 2.851

3.  Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial.

Authors:  Christina Schnopp; Roland Remling; Matthias Möhrenschlager; Lorenz Weigl; Johannes Ring; Dietrich Abeck
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

4.  Guideline on the management of hand eczema ICD-10 Code: L20. L23. L24. L25. L30.

Authors:  Thomas L Diepgen; Peter Elsner; Sibylle Schliemann; Manigé Fartasch; Arno Köllner; Christoph Skudlik; Swen M John; Margitta Worm
Journal:  J Dtsch Dermatol Ges       Date:  2009-05       Impact factor: 5.584

5.  Occupational skin diseases.

Authors:  Thomas L Diepgen
Journal:  J Dtsch Dermatol Ges       Date:  2012-03-27       Impact factor: 5.584

Review 6.  Topical pimecrolimus for skin disease other than atopic dermatitis.

Authors:  Uwe Wollina; Gesina Hansel; André Koch; Mohamed Badawy Abdel-Naser
Journal:  Expert Opin Pharmacother       Date:  2006-10       Impact factor: 3.889

Review 7.  [Cooperation among clinics and practices. Integrated medical care in occupational dermatology].

Authors:  C Skudlik; M Jünger; K Palsherm; K Breuer; S Brandenburg; S M John
Journal:  Hautarzt       Date:  2009-09       Impact factor: 0.751

Review 8.  [New and rarley used treatment options for refractory hand eczema: local UVA-1 phototherapy, retinoids, calcineurin inhibitors].

Authors:  U Raap; C Kenneweg; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2008-09       Impact factor: 0.751

9.  Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis.

Authors:  Donald V Belsito; Joseph F Fowler; James G Marks; David M Pariser; Jon Hanifin; Ida Alzira Gomes Duarte; Mario C Pires; Ponciano D Cruz; Richard G B Langley; Premal Patel; Christopher Bush; Mark Thurston; Michael Graeber; Robert Cherill
Journal:  Cutis       Date:  2004-01

10.  Cyclosporin A responsive chronic severe vesicular hand eczema.

Authors:  C S Petersen; T Menné
Journal:  Acta Derm Venereol       Date:  1992-11       Impact factor: 4.437

View more
  3 in total

1.  [Current trends in occupational dermatology].

Authors:  Christoph Skudlik; Johannes Geier; Swen Malte John
Journal:  Hautarzt       Date:  2014-11       Impact factor: 0.751

2.  [Scabies as an occupational disease].

Authors:  J Lukács; S Schliemann; P Elsner
Journal:  Hautarzt       Date:  2015-03       Impact factor: 0.751

3.  [Individual in-patient and out-patient prevention in occupational skin diseases].

Authors:  C Skudlik; E Weisshaar
Journal:  Hautarzt       Date:  2015-03       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.